No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ENTA240621C12500
- 0.80
- +0.15+23.08%
15min DelayClose May 31 15:59 ET
0.80High0.80Low
0.80Open0.65Pre Close10 Volume45 Open Interest12.50Strike Price800.00Turnover70.58%IV6.66%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.80Time Value100Contract SizeAmericanOptions Type0.5328Delta0.1985Gamma15.59Leverage Ratio-0.0222Theta0.0030Rho8.30Eff Leverage0.0113Vega
Intraday
- 5D
- 1D
News
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virolog
Express News | Enanta Pharmaceuticals Inc : Evercore ISI Cuts Target Price to $30 From $35
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders are probably feeling a little disappointed, since its shares fell 8.3% to US$12.76 in the week after its latest quarterly results. Revenue
Enanta Pharmaceuticals | 10-Q: Quarterly report
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Comments
Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth 1
Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.
The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.
Upgrades
• $A.O. Smith(AOS.US$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet(DNB.US$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning(GLW.US$ : CFRA Upgrades to Strong Buy ...
• $A.O. Smith(AOS.US$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet(DNB.US$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning(GLW.US$ : CFRA Upgrades to Strong Buy ...
8
Read more